Evidence map›Paper›PMID 32334465›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2020

Immunohistochemical Expression of BRCA1 Protein, ER, PR and Her2/neu in Breast Cancer: A Clinicopathological Study.

Israa A Hussein, Shatha Th Ahmed, Ameer D Hameedi, Rana Z Naji, Layth Alharbawi, Muzahm Alkhaytt, Intisar S Pity

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Type I or Type II Endometrial Carcinoma? Role of BRCA1 Immunohistochemistry.Asian Pacific journal of cancer prevention : APJCP · 2024
    Article
  5. Article
  6. Article
  7. Hereditary Breast and Ovarian Cancer Screening Syndrome Profile in Women Diagnosed with Breast Cancer from Paraná State Southwest.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Israa A HusseinMBChB, FIBMS Pathology, Department of Pathology, College of Medicine, University of Baghdad, Baghdad, Iraq.
Shatha Th AhmedMBChB, PhD mol. Pathology/ UK, College of Medicine, Ninevah University, Baghdad , Iraq.ORCID 0000-0002-8990-4211
Ameer D HameediMBChB, FIBMS Pathology, Department of Pathology, College of Medicine, University of Baghdad, Baghdad, Iraq.
Rana Z NajiMBChB, FIBMS Pathology,Oncology Teaching Hospital, College of Medicine, University of Duhok, Baghdad , Iraq.
Layth AlharbawiMBChB, CABS, General Surgeon, College of Medicine, Ninevah University, Baghdad, Iraq.
Muzahm AlkhayttMBChB, FRCS, President of Nineveh University, Ninevah University, Baghdad , Iraq.
Intisar S PityMD, FIBMS, Pathology, College of Medicine, University of Duhok, Baghdad, Iraq.
University of Baghdad · IQUniversity of Duhok · IQAl-Nisour University College · IQ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer is a heterogeneous hormone-dependent disease. Potential prognosis depends on the clinicopathological evaluation and assessment of other prognostic indicators. The detection of the oestrogen Receptor (ER), Progesterone Receptor (PR), Human epidermal growth factor receptor 2 (Her2/neu) and BRCA1 oncoprotein is pivotal for prognostic evaluation and to choose the appropriate post-surgical adjuvant therapy beside selecting the proper candidate for genetic counselling.

objectivesTo detect the immunoexpression of the BRCA1 oncoprotein in mammary invasive ducal carcinoma and its association with the prognostic markers (ER, PR and Her2/neu hormonal receptors) and other clinicopathological parameters to improve the patients' treatment plans.

methodsA cross-sectional study design including 83 paraffin blocks and histological slides collected from Al-Jumhoori Medical City Teaching Hospital Laboratory in Mosul and the Central Public Health Laboratory in Baghdad between the 1st of January 2010 to the 13th of March 2012 for patients diagnosed with primary invasive ductal breast carcinomas. Immunohistochemistry (IHC) using monoclonal antibodies against ER, PR, Her2/neu receptors and BRCA1 protein was performed via the fully automated immunostaining instrument 'Ventana Benchmark'.

resultsBRCA1 protein immunoexpression was detected in 20.5% of cases. It was significantly high with increasing tumour grade and stage. Although there was a trend of BRCA1 negativity toward negative ER, PR and Her2 receptors, no significant associations were observed with any of these parameters and the patients' age.

conclusionAltered BRCA1 expression is significantly associated with advanced tumour grade and stage. High number of cases with negative BRCA1 expression showed negative ER, PR and Her2/neu expression.

Indexed as

AdultAgedBiomarkers, TumorBRCA1 ProteinBreast NeoplasmsCarcinoma, Ductal, BreastCross-Sectional StudiesErb-b2 Receptor Tyrosine KinasesFemaleFollow-Up StudiesHumansImmunohistochemistryMiddle AgedPrognosisReceptors, EstrogenReceptors, ProgesteroneBiomarkers, TumorBRCA1 ProteinBRCA1 protein, humanERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneBRCA Oncoproteinbreast cancerimmunohistochemistry

Identifiers

PMID32334465
PMCPMC7445993
OpenAlexW3018543221

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.